IMRN

Immuron
IMRN
Market cap $10.5M

1.84 USD

+0.03

1.66%

At close Nov 18, 4:00 PM EST

1 day

1.66%

5 days

2.22%

1 month

-3.66%

3 months

-25.81%

6 months

-20.69%

Year to date

-3.16%

1 year

1.10%

5 years

-45.88%

10 years

-77.99%

About: Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Employees: 7

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% less ownership

Funds ownership: 0.01% [Q2] → 0% (-0%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

25% less funds holding

Funds holding: 4 [Q2] → 3 (-1) [Q3]

27% less capital invested

Capital invested by funds: $40.2K [Q2] → $29.2K (-$10.9K) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

172%

upside

Avg. target

$5

172%

upside

High target

$5

172%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Litchfield Hills

Sally Yanchus

0 / 0 met price target

172%upside

$5

Buy

Initiated

26 Sept 2024

See Analyst Rankings

Financial journalist opinion

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time).

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Immuron Travelan® continued strong sales growth

MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Immuron Travelan® continued strong sales growth

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC).

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline Insight, 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler's Diarrhea pipeline landscape is provided which includes the disease overview and Traveler's Diarrhea treatment guidelines.

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has received favourable feedback from the United States Food and Drug Administration (FDA) on the pre-IND (investigational new drug) information package to support the clinical development of IMM-529.

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA.

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22nd, 2024.

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on:

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

See News Rankings

Charts implemented using Lightweight Charts™